Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $156.8 million.

  • Tg Therapeutics' Total Current Liabilities rose 2533.37% to $156.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $156.8 million, marking a year-over-year increase of 2533.37%. This contributed to the annual value of $90.7 million for FY2024, which is 6879.93% up from last year.
  • As of Q3 2025, Tg Therapeutics' Total Current Liabilities stood at $156.8 million, which was up 2533.37% from $171.9 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Total Current Liabilities ranged from a high of $171.9 million in Q2 2025 and a low of $36.4 million during Q3 2022
  • Moreover, its 5-year median value for Total Current Liabilities was $87.6 million (2021), whereas its average is $88.5 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first plummeted by 5841.99% in 2022, then skyrocketed by 11691.81% in 2024.
  • Tg Therapeutics' Total Current Liabilities (Quarter) stood at $65.4 million in 2021, then dropped by 18.63% to $53.2 million in 2022, then grew by 0.98% to $53.7 million in 2023, then skyrocketed by 68.8% to $90.7 million in 2024, then surged by 72.93% to $156.8 million in 2025.
  • Its Total Current Liabilities stands at $156.8 million for Q3 2025, versus $171.9 million for Q2 2025 and $160.2 million for Q1 2025.